INTRODUCTION : Il a été démontré que le nombre de lipoprotéines apolipoprotéine B (apoB) est un prédicteur du développement du diabète de type 2 (DT2), mais le mécanisme est inconnu. La résistance à l'insuline (RI) et l'hyperinsulinémie compensatoire (HI) entraînent l’épuisement des cellules β et la progression vers le DT2. De plus, l'activation du système de l'interleukine -1β (IL- 1β) est impliquée dans la pathophysiologie du DT2. Notre objectif était donc d'étudier si l’apoB est associé à la RI et à l’HI chez les humains et si cette corrélation est médiée par l’activation du système IL-1β. MÉTHODOLOGIE : 47 femmes ménopausées, non diabétiques, obèses ou en surpoids et 28 hommes, âgés de 45 à 74 ans ont été recrutés. La sécrétion d'insuline (SI) et la sensibilité à l'insuline ont été mesurées par un clamp Botnia modifié. La 1ère et 2ème phase de SI furent mesurées lors d'un test de tolérance au glucose intraveineux (IVGTT) d’une heure, suivi d’un clamp hyperinsulinémique euglycémique (HEIC) de 3 heures (taux de perfusion d'insuline de 75 mU/m2/min) pour mesurer la sensibilité à l'insuline lors des 30 dernières minutes du clamp (état d'équilibre). La sensibilité à l'insuline est exprimée comme étant le taux de perfusion de glucose (GIR) seul ou divisé par le taux d’insuline à l’état d’équilibre (M/I). RÉSULTATS : Chez les femmes, l’apoB à jeun corrélait avec une augmentation de la 2e phase de SI, la SI totale et la sécrétion totale de C-peptide (r=0,202; r=0,168; r=0,204) et avec une diminution de la sensibilité à l'insuline (GIR r=-0,299; M/I r=-0,180) indépendamment de l'adiposité. L’IL-1Ra à jeun (indicateur de l’activation du système IL-1β) corrélait positivement avec la 2e phase, la SI totale et la sécrétion totale de C-peptide (r=0,217; r=0,154; r=0,198) et négativement avec la sensibilité à l'insuline (GIR r=-0,304; M/I r=-0,214). L’IL-1Ra était également corrélée avec l'apoB (r=0,352). Une fois corrigé pour l'IL-1Ra, toutes les associations entre l'apoB et les indices de sensibilité à l'insuline et de SI ont été perdues. Malgré des glycémies similaires, il n’y avait pas de corrélation de l’apoB avec les indices mesurés chez les hommes. CONCLUSION : L’apoB est associé à l’HI et la RI chez les femmes non diabétiques obèses et en surpoids, potentiellement via l'activation du système IL-1β. Ces différences sexuelles doivent être prises en compte dans l'exploration de la physiopathologie du DT2. / INTRODUCTION: The number of plasma apolipoprotein B lipoproteins (apoB) is reported to predict the development of type 2 diabetes (T2D); however the underlying mechanism is unknown. Insulin resistance (IR) and compensatory hyperinsulinemia (HI) are believed to promote β-cell exhaustion and progression to T2D. Moreover, the activation of the interleukin-1β (IL-1β) system is implicated in the pathophysiology of T2D. Our aim was thus to investigate whether plasma apoB associates with IR and HI in humans and whether this is mediated through the IL-1β system. METHODOLOGY: 47 non-diabetic overweight and obese postmenopausal women and 28 men, 45-74 years old were recruited. Insulin secretion (IS) and insulin sensitivity were examined by a modified Botnia clamp. 1st and 2nd phase IS were measured during a 1 hour intravenous glucose tolerance test (IVGTT), followed by a 3 hour hyperinsulinemic-euglycemic clamp (HEIC, insulin infusion rate of 75 mU/m2/min) to measure insulin sensitivity during the last 30 minutes of the clamp (steady state). Insulin sensitivity was expressed as steady state glucose infusion rate (GIR) alone or divided over steady state plasma insulin (M/I). RESULTS: In women, fasting plasma apoB correlated positively with increased 2nd phase and total IS and with total C-peptide secretion (r=0.202; r=0.168; r=0.204 respectively) and negatively with insulin sensitivity (r: GIR= -0.299 and M/I =-0.180) independent of adiposity. Similar to plasma apoB, fasting plasma IL-Ra (indicator of activated IL-1β system) correlated positively with 2nd phase and total IS and with total C-peptide secretion (r=0.217; r=0.154; r=0.198 respectively) and negatively with insulin sensitivity (GIR r=-0.304; M/I r=-0.214). Fasting plasma IL-Ra also correlated with apoB r=0.352). Once corrected for IL-1Ra, the associations between apoB and the indexes of insulin sensitivity and IS were all lost. Despite similar fasting glucose, plasma apoB did not correlate with any indices of insulin secretion or sensitivity in men. CONCLUSION: ApoB is associated with HI and IR in non-diabetic overweight and obese women, which may be mediated through activation of the IL-1β system. Gender differences may need to be considered in exploring the pathophysiology of T2D in humans.

OBJECTIF: L’apoB plasmatique prédit le diabète de type 2 chez l’humain. Une clairance ralentie des triglycérides (TG) favorise la lipotoxicité et la résistance à l’insuline (RI). Nous avons démontré ex vivo que les LDL, forme majeure d’apoB-lipoprotéines, altèrent le stockage des gras dans le tissu adipeux blanc (TAB) humain. Nous émettons l’hypothèse que le lien reliant l’apoB plasmatique à la RI et l’hyperinsulinémie est médié par un retard de clairance des gras diététiques. MÉTHODE/RÉSULTATS: Nous avons examiné la sécrétion d’insuline (SI), puis la RI lors d’un test de tolérance au glucose intraveineux suivi d’un clamp hyperinsulinémique-euglycémique chez des sujets obèses normoglycémiques (N=29, 45%hommes, indice de masse corporelle (IMC)≥27kg/m2, 45-74ans, post-ménopausés). La clairance des TG diététiques a été mesurée suivant l’ingestion d’un repas gras marqué au 13C. La fonction d’une biopsie de TAB (à jeun) a été mesurée comme la capacité à stocker un substrat de 3H-TG. L’apoB était de 1,03±0,05g/L et corrélait avec la RI, la 2ième phase de SI, un délai de clairance des TG diététiques et une réduction de la fonction du TAB. Un retard de clairance des TG diététiques était associé à la RI et la 2ième phase de SI. Une correction pour la clairance des TG diététiques ou la fonction du TAB a éliminé l’association entre l’apoB et la RI et la 2ième phase de SI. CONCLUSION: L’association entre l’apoB plasmatique et la RI et la SI chez les sujets obèses est médiée par une clairance ralentie des gras diététiques et une dysfonction du TAB. / OBJECTIVE: Plasma apoB predicts type 2 diabetes in humans. Delayed TG clearance promotes lipotoxicity and insulin resistance (IR). We demonstrated ex vivo that LDL, the major form of apoB-lipoproteins, impairs human white adipose tissue (WAT) fat storage. We hypothesized that the link between plasma apoB, IR and hyperinsulinemia is mediated through delayed dietary fat clearance. METHODS/RESULTS: We examined insulin secretion (IS) and IR during a intravenous-glucose tolerance test followed by a hyperinsulinemic-euglycemic clamp in normoglycemic obese (N=29, 45%men, body mass index (BMI)≥27kg/m2, 45-74yrs, postmenopausal). Dietary TG clearance was measured after the ingestion of a 13C-triolein-labeled high-fat meal. The function of a fasting WAT biopsy was measured as the ability to store a 3H-TG substrate. Plasma apoB averaged 1.03±0.05g/L, and correlated with IR, 2nd phase IS, delayed dietary TG clearance and reduced WAT function. Moreover, delayed dietary TG clearance was associated with higher IR and 2nd phase IS. Correcting for dietary TG clearance or WAT function eliminated the association of plasma apoB with IR and 2nd phase IS. CONCLUSION: The association of plasma apoB with IR and IS in obese subjects is mediated by delayed dietary fat clearance and WAT dysfunction.

Dans le diabète de type 2 établi, l'hyperglycémie chronique, un taux élevé d'acides gras libres et l'inflammation induisent un stress oxydatif (SO) au niveau de la cellule beta. Le SO, qui apparaît dès le stade de pré-diabète, peut induire un dysfonctionnement précoce de cette cellule. Ainsi, la protection de la cellule β par des molécules anti-oxydantes pourrait ralentir la progression du pré-diabète au diabète.La quercétine, un flavonoïde, a présenté des propriétés antidiabétiques dans plusieurs études in vivo. Cependant, très peu de données traitent de son mécanisme d'action directement au niveau de la cellule beta. Dans ce contexte, nous avons étudié les effets de la quercétine au niveau de la cellule beta dans des conditions physiologiques et des conditions de SO.Nos résultats montrent qu'en présence de concentrations stimulantes de sécrétagogue, la quercétine potentialise la sécrétion d'insuline par un mécanisme impliquant l'augmentation de calcium intracellulaire et la potentialisation de ERK1/2 via l'activation des voies de la PKA et de la CaMK II. De plus, la quercétine protège la cellule beta du SO en sur-activant ERK1/2. Le resvératrol et la NAC, deux antioxydants de référence, sont inactifs dans ces conditions expérimentales.En absence de concentrations stimulantes de sécrétagogue, la quercétine induit une sécrétion d'insuline modérée en augmentant le calcium intracellulaire suite à une activation directe des CaV de type L. Dans ces conditions, l'activation de ERK1/2 induite par la quercétine, qui est indépendante de l'activation des voies de la PKA et de la CaMK II, ne serait pas impliquée dans le mécanisme sécrétoire. Nos résultats indiquent que le mécanisme d'action de la quercétine au niveau de la cellule β ne repose pas uniquement sur ses capacités anti-oxydantes mais fait intervenir des cibles pharmacologiques et la régulation de voies de signalisation intracellulaires. / In type 2 diabetes, chronic hyperglycaemia, elevated free fatty acids and inflammation induce oxidative stress (OS) in pancreatic β cell. SO, which appears at the stage of pre-diabetes, may induce early dysfunction of this cell. Thus, the β cell protection by antioxidant molecules could slow the progression of pre-diabetes to diabetes.Quercetin, a flavonoid, has shown antidiabetic properties in several in vivo studies. However, very few data address its mechanism of action directly at the β cell. In this context, we studied the effects of quercetin at the β cell under physiological conditions and conditions of OS.Our results show that in the presence of stimulating concentrations of secretagogue, quercetin potentiates insulin secretion by a mechanism involving increased intracellular calcium and potentiation of ERK1 / 2 via activation of the PKA and the CaMK II pathways. In addition, quercetin protects beta cell from OS via a suractivation of ERK1/2. Resveratrol and NAC, two antioxidants of reference are inactive under these experimental conditions.In the absence of stimulating concentration of secretagogue, quercetin induced moderate insulin secretion by increasing the intracellular calcium via a direct activation of L-type CaV Under these conditions, the activation of ERK1/2 induced by quercetin, which is independent of the activation pathways of PKA and CaMK II to, would not be involved in the secretory mechanism.Our results indicate that the mechanism of action of quercetin at the β cell not only based on its antioxidant capacity but involves pharmacological targets and the regulation of intracellular signaling pathways.

Mitochondrial uncoupling proteins (UCPs) belong to the superfamily of mitochondrial anion-carriers. The longest known is UCP1, predominantly expressed in brown adipose tissue, where it takes part in nonshivering thermogenesis. In the late 1990s were discovered other sequence homologs of UCP1 with tissue specific distribution. The Function of these "new" uncoupling proteins is still uncertain. It is assumed that each of the isoforms has a specific function depending on the type of tissue. This thesis showed differences in tissue transcription pattern between rat and mice using RT-PCR absolute quantification. Significant differences in pattern were found in lungs, brain and muscle. In each case UCP expression was higher in mice tissues. Mice lungs express mainly UCP2. The difference in mice brain is caused by ucp4 and ucp5 genes transcription and finally in muscle is highest content of UCP3 mRNA. We investigated whether any of ucp transcript can complement ucp2 transcripton in spleen or lungs of ucp2 -/- mice. We did not find any difference which can explain, that in isolated lung mitochondria of fasted ucp2-/- mice were uncoupled in state 4. In the last project, we found relationship between ucp2 transcription in insulinoma INS-1E cells and oxygen levels of the cultivation atmosphere.

O estresse oxidativo e a enzima NADPH oxidase-2 (NOX2) estão associados com a diminuição da massa funcional de células-β em pacientes com diabetes do tipo 2 (DT2). Neste estudo, testamos o papel da NOX2 sobre a glicotoxicidade em células-β. Ilhotas de camundongo C57BL/6J nocautes ou não para NOX2 (NOX2-KO e WT, respectivamente) foram isoladas e cultivadas por até 3 semanas em 10 ou 30 mmol/l de glucose (G10 e G30, respectivamente). A secreção de insulina foi maior nas ilhotas NOX2-KO vs. WT sem apresentar diferenças metabólicas ou do potencial redox da glutationa citosólica (EGSH). O cultivo de ilhotas em G30 aumenta a concentração de H2O2 e a oxidação de tióis no compartimento citosólico, seguido por aumento de apoptose de células-β, mas, preservando a reposta máxima secretória. Estas respostas foram quase idênticas em ambos os tipos de ilhotas. Em conclusão, a NOX2 regula negativamente a secreção de insulina em ilhotas de camundongos C57BL/6J, mas não é um componente crítico para a sobrevivência de células β em um modelo in vitro de glicotoxicidade. / Oxidative stress and NADPH oxidase-2 (NOX2) enzyme are associated to the decline of the functional β-cell mass in type 2 diabetes (T2D). Here, we tested the role of NOX2 on β-cell glucotoxicity. NOX2 knockout (NOX2 KO) and wild type (WT) C57BL/6J mice islets were isolated and cultured up to 3 weeks at 10 or 30 mmol/l glucose concentrations (G10 and G30, respectively). The insulin secretion was higher in NOX2-KO vs. WT islets despite similar metabolic and cytosolic glutathione-redox potential (EGSH) changes. The prolonged culture at G30 increases the H2O2 concentration and cytosolic thiol oxidation, followed by increased βcell apoptosis but preserving maximal secretory response. These responses were almost identical in both types of islets. In conclusion, NOX2 is a negative regulator of insulin secretion in C57BL/6J mouse islets, but is not a critical component for β-cell survival in a model of glucotoxicity in vitro.

A Arginina (Arg) regula a secreção de GH e insulina, e é o único precursor biológico do NO. Previamente demonstramos que animais tratados cronicamente com Arg (35mg/dia) desenvolvem resistência à insulina (RI), e o presente estudo investigou as suas bases moleculares. A RI baseou-se na redução da atividade e/ou expressão do IRS 1/2 e Akt, e do conteúdo de GLUT4; sendo o GH crucial na gênese desses efeitos. Doses mais elevadas de Arg (70mg/dia/30 dias), a maior geração de NO e a melhora do fluxo sangüíneo reverteram este quadro. Experimentos com células musculares demonstraram que a Arg estimula o metabolismo de glicose e lipídios, via NO/c-GMP. Esses achados indicam que a Arg pode ser benéfica para o tratamento de distúrbios metabólicos, como obesidade e DM2; e que ao estimular a secreção de GH, em doses adequadas, seria eficaz na terapia de distúrbios da secreção deste hormônio. Todavia, estudos adicionais são necessários para investigar a melhor dose e os efeitos crônicos in vivo da Arg, uma vez que o GH em excesso apresenta um efeito diabetogênico importante. / Arginine (Arg) regulates the secretion of GH and insulin, and it is the main biological precursor of NO. We have previously shown that animals chronically-treated with Arg (35 mg/day) developed insulin resistance (IR), and this study investigated its molecular basis. The RI relies on the reduction of the activity and/or expression of IRS 1/2 and Akt, and of the GLUT4 content; and GH has a crucial role in the genesis of these effects. Higher doses of Arg (70 mg/dia/30 days), the increased NO generation and the improvement of the blood flow reversed the RI. Experiments with muscle cells showed that Arg stimulates glucose and lipids metabolism, via NO/c-GMP activation. These findings indicate that Arg may be beneficial for the treatment of metabolic disorders, such as obesity and T2DM, and by stimulating GH secretion, Arg can, in appropriate doses, be effective for the therapy of GH secretion disorders. However, further studies are needed to investigate the best dose and the chronic effects of Arg in vivo, since that GH in excess is potentially diabetogenic.

Os ácidos graxos (AG) podem influenciar o processo secretório de insulina induzido pela glicose. Os AG ω3 interferem em diversos processos fisiológicos, sendo que nas ilhotas pancreáticas, os AG ω3 colaboram para a diminuição da lipotoxicidade induzida pelo ácido palmítico. Ao ácido palmítico são atribuídos efeitos deletérios em diversos tecidos, assim como nas células β, onde ele promove a alteração da composição dos fosfolípides de membrana, do potencial elétrico da mesma e consequentemente do processo de extrusão dos grânulos de insulina. A exposição crônica das células β ao excesso de ácido palmítico é tóxica, provocando diminuição da resposta secretória de insulina, redução da oxidação e captação de glicose e aumento de espécies reativas de oxigênio (EROs) que, em quantidades suprafisiológicas, irão contribuir para a falência e morte da célula β. As EROs podem ser de origem mitocondrial, através do metabolismo dos nutrientes ou ainda proveniente da ativação do complexo enzimático NADPH oxidase, o qual é modulado pela glicose e pelos AG, incluindo o ácido palmítico. Em contrapartida, os AG ω3 exercem efeitos anti-inflamatórios e antioxidantes em diversos sistemas, contribuindo para melhora de perfil lipídico e resistência periférica à insulina. O objetivo deste trabalho foi verificar o possível efeito protetor dos AG ω3 contra os efeitos deletérios do ácido palmítico em células β pancreáticas. Nas células β, a partir dos resultados obtidos, a presença de AG ω3 mostrou-se eficaz para prevenir o dano secretório e o aumento de EROs, além de contribuir para manutenção da viabilidade celular e da captação de glicose nas ilhotas tratadas com ácido palmítico, desempenhando um importante papel protetor na célula β. / Fatty acids (FA) may influence the process of glucose-induced insulin. The ω3 FA interferes in several physiological processes, and in the pancreatic islets collaborate to decrease the lipotoxicity induced by palmitic acid. Palmitic acid induces deleterious effects in several tissues, as well as in β cells, where it promotes the alteration of the membrane phospholipid composition, the plasma membrane electric potential, and consequently, the process of the insulin granules extrusion. Chronic exposure of β cells to high concentration of palmitic acid is toxic, leading to decreased insulin secretory response, reduced oxidation and uptake of glucose, and an increase in reactive oxygen species (ROS) which, in supraphysiological amounts, will contribute to β-cell failure and death. ROS may be of mitochondrial origin, through the metabolism of nutrients or even from the activation of the enzymatic complex NADPH oxidase, which is modulated by glucose and FA, including palmitic acid. In contrast, ω3 FA exerts anti-inflammatory and antioxidant effects in several systems, contributing to the improvement of lipid profile and peripheral resistance to insulin. The aim of this study was verify the protective possible effect of AG ω3 against the deleterious effects of palmitic acid on pancreatic β cells. Our results shown that the presence of ω3 FA was effective in preventing secretory damage and increase of EROs, also contributing to the maintenance of cell viability and glucose uptake in the islets treated with palmitic acid, playing an important β-cell protective role.

Neste projeto, demonstramos a modulação da enzima NAD(P)H oxidase pela glicose, palmitato e interleucina - 1? através da análise da expressão protéica do componente p47PHOX e pela atividade dessa enzima via produção de superóxido e peróxido de hidrogênio. Demonstramos também a participação da enzima NAD(P)H oxidase no processo de secreção de insulina induzido pela glicose pois a inibição da enzima pelo DPI e oligonucleotídeo anti p47PHOX promoveu uma diminuição da secreção do hormônio. A partir desse dado passamos a avaliar o mecanismo de ação da enzima no processo secretório e demonstramos que a inibição dessa enzima promove uma inibição de genes essenciais no processo de secreção de insulina como GLUT-2 e glicocinase.Assim podemos concluir que a enzima NAD(P)H oxidase é modulada pela glicose, palmitato e interleucina 1? e que essa enzima participa do processo de secreção insulina modulando genes essenciais para o processo secretório como GLUT-2 e glicocinase. / The expression and activity of the componenents of NAD(P)H oxidase in pancreatic islets were described for the first time in our laboratory (OLIVEIRA, HR et ai, 2003). It was shown the gene and protein expression of the components of this enzyme in Seta cells and that enzyme activation is mediated by glucose. Glucose induced insulin secretion was followed by increase in EROS generation and this increase was in part mediated by NAD(P)H oxidase activation (the same mechanism observed in phagocytes). In this study, the modulation of NAD(P)H oxidase activity by glucose, palmitate and interleukin 1ß as investigated through protein expression of p47phox vity of this enzyme through superoxide and hydrogen peroxide production. To determinate the role of NAD(P)H oxidase in the process of glucoseinduced insulin secretion the enzyme was inhibited by DPI and oligonucleotide anti p47phox, in the both cases the enzyme inhibition produced a decrease on insulin secretion. In order to investigated NAD(P)H oxidase mechanism of action in insulin secretion, we shown that the inhibition enzyme by DPI reduced the GLUT-2 and glucokinase gene expression. We can concluded hat NAD(P)H oxidase was modulated by glucose, palmitate and interleukin 1ß and that enzyme participed in process of glucoseinduced insulin secretion through modulation of GLUT-2 and glucokinase gene expression.

Type 1 diabetes (T1D) is a chronic autoimmune disease targeted against the pancreatic β-cells. Proinflammatory cytokines are considered to play a major role in the destruction of the insulin-producing β-cells. This thesis studied strategies to counteract proinflammatory cytokines in experimental T1D. Both animal models for T1D as well as β-cell preparations exposed in vitro to putative noxious conditions were examined. In the first study we observed that cytokine treatment of mouse pancreatic islets lacking inducible nitric oxide synthase (iNOS) induced a prolongation of the early stimulatory phase of glucose stimulated insulin secretion. Various experiments led to the conclusion that this prolonged stimulatory effect may involve the DAG/PLD/PKC pathway. Next, we transplanted mouse islets deficient in iNOS to spontaneously diabetic NOD mice. We observed a normalization of hyperglycemia but not a delayed allograft rejection compared to transplanted wild type islets. Thus, absence of iNOS in the graft was not sufficient to prolong allograft survival. In paper III we found that sustained glucose stimulation of rat pancreatic islets was coupled to a decreased conversion of proinsulin to insulin. Islet treatment with IL-1β was also coupled to a decreased proinsulin conversion. Islet proconvertase activity may be a target in islet damage. In paper IV prolactin (PRL) was administered to mice in the multiple low dose streptozotocin model and we observed that PRL enhanced a Th2 response. This may contribute to the protective action by PRL in this model of autoimmune T1D. Finally, by examining β-cells overexpressing Suppressor of cytokine signalling 3 (SOCS-3) it was found that this could inhibit IL-1β induced signalling through the NF-κB and MAPK pathways. SOCS-3 overexpression also inhibited apoptosis induced by cytokines in primary β-cells. Lastly, we demonstrated that SOCS-3 transgenic islets were protected in an allogeneic transplantation model.

Insulin and glucagon are released in pulses from pancreatic β- and α-cells, respectively. Both cell types are electrically excitable, and elevation of the cytoplasmic Ca2+ concentration ([Ca2+]i) due to depolarization with voltage-dependent entry of the cation is the main trigger of hormone secretion. Store-operated Ca2+ entry  (SOCE) also contributes to the [Ca2+]i elevation and this process has been suggested to be particularly important for glucagon secretion. cAMP is another important messenger that amplifies Ca2+-triggered secretion of both hormones, but little is known about cAMP dynamics in islet cells. In type-2 diabetes, there is deteriorated β-cell function associated with elevated concentrations of fatty acids, but the underlying mechanisms are largely unknown. To clarify the processes that regulate insulin and glucagon secretion, cAMP signalling and the store-operated pathway were investigated in β- and α-cells, primarily within their natural environment in intact mouse and human islets of Langerhans. Fluorescent biosensors and total internal reflection microscopy were used to investigate signalling specifically at the plasma membrane (PM). Adrenaline increased and decreased the sub-PM cAMP concentration ([cAMP]pm) in immuno-identified α-cells and β-cells, respectively, which facilitated cell identification. Glucagon elicited [cAMP]pm oscillations in α- and β-cells, demonstrating both auto- and paracrine effects of the hormone. Whereas glucagon-like peptide 1 (GLP-1) consistently elevated [cAMP]pm in β-cells, only few α-cells responded, indicating that GLP-1 regulates glucagon secretion without changes of α-cell [cAMP]pm. Both α- and β-cells responded to glucose with pronounced oscillations of [cAMP]pm that were partially Ca2+-dependent and synchronized among islet β-cells. The glucose-induced cAMP formation was mediated by plasma membrane-bound adenylyl cyclases. Several phosphodiesterases (PDEs), including the PDE1, -3, -4, and -8 families, were required for shaping the [cAMP]pm signals and pulsatile insulin secretion. Prolonged exposure of islets to the fatty acid palmitate deteriorated glucose-stimulated insulin secretion with loss of pulsatility. This defect was associated with impaired cAMP generation, while [Ca2+]i signalling was essentially unaffected. Stromal interacting molecule 1 (STIM1) is critical for activation of SOCE by sensing the Ca2+ concentration in the endoplasmic reticulum (ER). ER Ca2+ depletion caused STIM1 aggregation, co-clustering with the PM Ca2+ channel protein Orai1 and SOCE activation. Glucose, which inhibits SOCE by filling the ER with Ca2+, reversed the PM association of STIM1. Consistent with a role of the store-operated pathway in glucagon secretion, this effect was maximal at the low glucose concentrations that inhibit glucagon release, whereas considerably higher concentrations were required in β-cells. Adrenaline induced STIM1 translocation to the PM in α-cells and the reverse process in β-cells, partially reflecting the opposite effects of adrenaline on cAMP in the two cell types. However, cAMP-induced STIM1 aggregates did not co-cluster with Orai1 or activate SOCE, indicating that STIM1 translocation can occur independently of Orai1 clustering and SOCE.